...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: ZHCLF

,,yes,,agreed,,,,KD is still in both plays,,,,,I learned a long time ago not to put all my eggs in one basket,,,,,fj can if he or she wants to but I wont,,,,,no matter how pitiful the management team is,,,,as noted and it might still not be clear to some investors,,,,,,I am not disturbed around the science,,,,thats what I bought into,,,,,unfortunately we bought with it a management team which clearly has not created the most progressive business model in order to advanced their science. Surely this is obvious. BTI is at least changing their strategy and has assembled impressive teams for direction and support,,,,,,RVX however is no where near as impressive,,,,,with a wedding planner for our CEO. This is a pesonal opinion.

Share
New Message
Please login to post a reply